Literature DB >> 26064257

Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer.

Baihong Guo1, Tuanjie Che2, Baoguang Shi1, Lijun Guo1, Zhihua Zhang1, Lin Li2, Chuanyong Cai2, Yirong Chen1.   

Abstract

OBJECTIVE: To detect the expression profile of bladder cancer and to delineate the interaction network of these genes in invasive bladder cancer.
METHODS: A total of 126 differentially expressed genes were identified, and input into STRING online database to delineate interaction network. The network data were screened with central nodes. The expression of genes with the most evident change in the exfoliated cells of urine was detected. RNA markers with over-expression in stage Ta tumor and/or T1 to T4 tumors but low expression in blood or inflammatory cells were characterized.
RESULTS: On the basis of assay of 21,639 whole-genome oligonucleotide microarray, a total of 126 differentially expressed genes were identified, of which 69 had up-regulated expression and 57 had down-regulated expression. STRING screening showed there were interactions among 103 genes in the bladder cancer which formed a complex network. A total of 23 central nodes were screened with Cytoscape and are involved in multiple signaling pathways related to tumorigenesis. The test specificity was 80% for the 30 control patients with urinary tract infections. The combination of BLCA-4 and HOXA13 could distinguish between low and high grade tumors, with specificity and sensitivity of 80%.
CONCLUSION: The interaction network of differentially expressed genes, especially the central nodes of this network, can provide evidence for the early diagnosis and molecular targeted therapy of invasive bladder cancer, and combined detection of IGF-1, hTERT, BLCA-4 and HOXA13 genes is helpful to evaluate BTCC at different stages.

Entities:  

Keywords:  Bladder transitional cell carcinoma; central nodes; interaction network; quantitative real-time PCR; urine marker

Year:  2015        PMID: 26064257      PMCID: PMC4443091     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

1.  Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings.

Authors:  L Bubendorf; B Grilli; G Sauter; M J Mihatsch; T C Gasser; P Dalquen
Journal:  Am J Clin Pathol       Date:  2001-07       Impact factor: 2.493

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  Dispersed Chromosomal Stat5b-binding elements mediate growth hormone-activated insulin-like growth factor-I gene transcription.

Authors:  Dennis J Chia; Ben Varco-Merth; Peter Rotwein
Journal:  J Biol Chem       Date:  2010-04-07       Impact factor: 5.157

Review 4.  The application of microarray technology to the analysis of the cancer genome.

Authors:  John K Cowell; Lesleyann Hawthorn
Journal:  Curr Mol Med       Date:  2007-02       Impact factor: 2.222

5.  Functional characterization of the bladder cancer marker, BLCA-4.

Authors:  Thu-Suong Van Le; Julie Myers; Badrinath R Konety; Timothy Barder; Robert H Getzenberg
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

6.  Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.

Authors:  Aiye Guo; Xiuhua Wang; Lan Gao; Juan Shi; Changyi Sun; Zhen Wan
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

7.  Urine-based assays for the detection of bladder cancer.

Authors:  Patrick Villicana; Bryant Whiting; Steve Goodison; Charles J Rosser
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

8.  Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder.

Authors:  Matteo Santoni; Francesco Catanzariti; Daniele Minardi; Luciano Burattini; Massimo Nabissi; Giovanni Muzzonigro; Stefano Cascinu; Giorgio Santoni
Journal:  Adv Urol       Date:  2012-07-02

Review 9.  IGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty.

Authors:  Marcello Maggio; Francesca De Vita; Fulvio Lauretani; Valeria Buttò; Giuliana Bondi; Chiara Cattabiani; Antonio Nouvenne; Tiziana Meschi; Elisabetta Dall'Aglio; Gian Paolo Ceda
Journal:  Nutrients       Date:  2013-10-21       Impact factor: 5.717

10.  Influencing factors on the NMP-22 urine assay: an experimental model.

Authors:  Makito Miyake; Steve Goodison; Evan Gomes Giacoia; Wasia Rizwani; Shanti Ross; Charles J Rosser
Journal:  BMC Urol       Date:  2012-08-28       Impact factor: 2.264

View more
  4 in total

1.  Dysregulated expression of homebox gene HOXA13 is correlated with the poor prognosis in bladder cancer.

Authors:  Haiyi Hu; Yuebing Chen; Sheng Cheng; Gonghui Li; Zhigen Zhang
Journal:  Wien Klin Wochenschr       Date:  2016-11-09       Impact factor: 1.704

2.  The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction.

Authors:  Yun Deng; Rongquan He; Rui Zhang; Binliang Gan; Yu Zhang; Gang Chen; Xiaohua Hu
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

3.  An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.

Authors:  Nouha Setti Boubaker; Aymone Gurtner; Nesrine Trabelsi; Isabella Manni; Ahlem Blel; Ahmed Saadi; Marouene Chakroun; Zeineb Naimi; Selim Zaghbib; Meriam Ksontini; Khedija Meddeb; Soumaya Rammeh; Haroun Ayed; Mohamed Chebil; Giulia Piaggio; Slah Ouerhani
Journal:  J Clin Lab Anal       Date:  2022-07-19       Impact factor: 3.124

4.  Modulation of IL-1β reprogrammes the tumor microenvironment to interrupt oral carcinogenesis.

Authors:  Tong Wu; Yun Hong; Lihua Jia; Jie Wu; Juan Xia; Juan Wang; Qinchao Hu; Bin Cheng
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.